Stellantis to Announce First Half 2025 Results on July 29
AMSTERDAM, July 2, 2025 - Stellantis N.V. announced today that its First Half 2025 Results will be released on Tuesday, July 29, 2025.
A live webcast and conference call of the First Half 2025 Results will begin at 2 p.m. CEST / 8 a.m. EDT on Tuesday, July 29, 2025.
The related press release and presentation material are expected to be posted under the Investors section of the Stellantis corporate website (www.stellantis.com) at approximately 8 a.m. CEST / 2 a.m. EDT on Tuesday, July 29, 2025.
Details for accessing this presentation are available under the Investors section of the Stellantis corporate website. For those unable to participate in the live session, a recorded replay will be accessible following the event.
# # #Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is a leading global automaker, dedicated to giving its customers the freedom to choose the way they move, embracing the latest technologies and creating value for all its stakeholders. Its unique portfolio of iconic and innovative brands includes Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, FIAT, Jeep®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. For more information, visit www.stellantis.com.
@Stellantis
Stellantis
Stellantis
Stellantis
For more information, contact:Fernão SILVEIRA +31 6 43 25 43 41 – fernao.silveira@stellantis.comNathalie ROUSSEL +33 6 87 77 41 82 – nathalie.roussel@stellantis.comcommunications@stellantis.comwww.stellantis.com
Attachment
EN-20250702-Stellantis-H1-2025-Results-Media-Advisory
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Eli Lilly raises full-year profit forecast on weight-loss drug strength
(Reuters) -Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy. However, shares of the U.S. drugmaker fell about 12% in premarket trading after it reported data from its oral weight loss drug, orforglipron, earlier in the day. Orforglipron helped patients lose 12.4% of their weight on average after 72 weeks. At least three analysts said the market had been looking for orforglipron to match Wegovy's 14.9% weight loss over 68 weeks, as shown in a 2021 trial, with some expecting the pill to surpass Novo's popular drug. Lilly competes with Danish drugmaker Novo Nordisk in the fast-growing market for weight-loss drugs known as GLP-1 agonists, which is expected to top $150 billion in revenue over the next decade. Last week, Novo cut its profit forecast for the second time this year, citing lower-than-expected U.S. growth and competition from cheaper copies of Wegovy made by compounding pharmacies. The company now expects to earn $21.75 to $23 per share on an adjusted basis this year, compared with its previous forecast for a profit of $20.78 to $22.28 per share. Analysts were expecting a profit of $21.74 per share for 2025, according to data compiled by LSEG. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Forbes
6 minutes ago
- Forbes
Swiss Shock - Can Switzerland Reverse The 39% Tariff?
The imposition of a 39% tariff on Swiss exports to the US has been greeted with shock, despair and much ire in Switzerland – the main newspaper NZZ greeting the move as 'absurd'. Considerable offense was taken by the fact that the announcement came on the Swiss National holiday (August 1st). Equally, local business leaders and economists have been perplexed by the fact that the tariffs have been calculated on the back of a trade deficit that was skewed by the export of gold – the deficit is now a surplus. Equally, many of the goods that Switzerland exports to the US, do not have competitors there (Swiss chocolate, watches and more importantly specialized industrial goods which are used by the likes of Boeing). Neither is the Swiss franc a weak currency. There is also a feeling in Switzerland that its role on the international stage, and facilitator of American diplomacy (the Swiss embassy in Tehran has traditionally acted 'for' the US), has gone un-noticed. Swiss politics is normally a very staid affair but this episode has led to infighting across the spectrum, and considerable blame has been focused on the President of the government Council, Karin Keller-Sutter. As a result, the Swiss negotiating team that will return to Washington this week will have representation from the conservative SVP, and more officials from the trade and finance divisions. The Swiss case highlights the flaws in the methodology of the White House approach. While its economy is extremely resilient, the Swiss will not be able to suffer a 39% tariff lightly. Our sense is that the counterargument will centre around a re-framing of the trade relationship between the two countries, a re-evaluation of how Swiss industry in particular helps US firms, and an undertaking for Swiss industry to invest in the US. The hope here is that Switzerland ends up with an EU style deal, of tariffs of 15%, and a somewhat empty promise to invest 'billions' into the US. From a diplomatic point of view, given that the Swiss had traditionally been so helpful to US interests, this is an own-goal by the White House. At the time of writing, there is no indication at all as to whether this episode pushes Switzerland closer to the EU (in terms of trade – there is no question of Switzerland joining the EU). For its part, the EU is still trying to get the White House to agree the wording of deal reached in Scotland – there is ongoing lobbying from the spirits industry in Europe, not to mention the auto manufacturers. The deal is not yet watertight and needs to be implemented by individual members. There is still uncertainty over the threats to place specific tariffs on semiconductors and pharmaceuticals firms based in Europe next week (Ireland in particular) and the USD 600bn that is supposed to be invested by European firms in the US. If sector specific tariffs are severe the backlash to the deal could grow and there is rising chance that it could fall apart.
Bloomberg
6 minutes ago
- Bloomberg
UK Sets New Rules on Surging Payments Sector After Client Losses
The UK 's financial watchdog imposed new rules on the payments sector aimed at protecting customer funds, the latest effort by the regulator to rein in an industry criticized for poor anti-fraud controls and reckless risk taking. Payments firms will have to carry out annual audits ensuring those funds are safe under rules starting next year, according to a statement from the Financial Conduct Authority. Companies in the sector that collapsed during 2018 and 2023 had an average 65% shortfall of consumers' money, it said.
